{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:15:14Z","timestamp":1788491714316,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hexal AG, a Sandoz company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1907-x","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:03:43Z","timestamp":1559055823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study"],"prefix":"10.1186","volume":"21","author":[{"given":"Janusz","family":"Jaworski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya H.","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeniusz J.","family":"Kucharz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Babic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"1907_CR1","volume-title":"Enbrel US Prescribing Information","author":"Amgen","year":"1998","unstructured":"Amgen. Enbrel US Prescribing Information, 1998. Available from \n                    http:\/\/pi.amgen.com\/united_states\/enbrel\/derm\/enbrel_pi.pdf\n                    \n                   Accessed 17 Aug 2018."},{"key":"1907_CR2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/bcp.13170","volume":"83","author":"O von Richter","year":"2017","unstructured":"von Richter O, Skerjanec A, Afonso M, Sanguino Heinrich S, Poetzl J, Woehling H, et al. GP2015, a proposed etanercept biosimilar: pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes. Br J Clin Pharmacol. 2017;83:732\u201341.","journal-title":"Br J Clin Pharmacol"},{"key":"1907_CR3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/bjd.15152","volume":"176","author":"CEM Griffiths","year":"2017","unstructured":"Griffiths CEM, Thaci D, Gerdes S, Arenberger P, Pulka G, Kingo K, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176:928\u201338.","journal-title":"Br J Dermatol"},{"key":"1907_CR4","doi-asserted-by":"crossref","unstructured":"Matucci-Cerinic M, Allanore Y, Kavanaugh A, Buch M, Schulze-Koops H, Kucharz EJ, et al. Efficacy, safety, and immunogenicity of GP2015, an etanercept biosimilar, compared to the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind, EQUIRA study. RMD Open J. 2018; in press.","DOI":"10.1136\/rmdopen-2018-000757"},{"key":"1907_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/rheumatology\/kes279","volume":"51","author":"J Kay","year":"2012","unstructured":"Kay J, Upchurch KS. ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012;51:5\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"1907_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.1780350502","volume":"35","author":"MC Hochberg","year":"1992","unstructured":"Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498\u2013502.","journal-title":"Arthritis Rheum"},{"key":"1907_CR7","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23:S93\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"1907_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2018t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44\u20138.","journal-title":"Arthritis Rheum"},{"key":"1907_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM Van Gestel","year":"1996","unstructured":"Van Gestel AM, Prevoo MLL, Van \u2018t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum. 1996;39:34\u201340.","journal-title":"Arthritis Rheum"},{"key":"1907_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137\u201345.","journal-title":"Arthritis Rheum"},{"key":"1907_CR11","first-page":"S14","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23:S14\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1907_CR12","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):811\u20139.","journal-title":"J Rheumatol"},{"key":"1907_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63\u201374.","journal-title":"J Pain Symptom Manage"},{"key":"1907_CR14","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1111\/jdv.14632","volume":"32","author":"J Poetzl","year":"2018","unstructured":"Poetzl J, Arlt I, von Richter O, W\u00f6hling H, Afonso M, Schaffar G. State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015. J Eur Acad Dermatol Venereol. 2018;32:e130\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1907_CR15","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76:1426\u201331.","journal-title":"Ann Rheum Dis"},{"key":"1907_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/art.40324","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70:60\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"1907_CR17","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304\u201316.","journal-title":"Lancet"},{"key":"1907_CR18","first-page":"3489","volume":"69","author":"D De Cock","year":"2017","unstructured":"De Cock D, Kearsley-Fleet L, Watson K, Hyrich KL. Switching from RA originator to biosimilar in routine clinical care: early data from the British Society for Rheumatology biologics register for rheumatoid arthritis. Arthritis Rheumatol. 2017;69:3489\u201391.","journal-title":"Arthritis Rheumatol"},{"key":"1907_CR19","unstructured":"FDA. Scientific Considerations in demonstrating biosimilarity to a reference product. Guidance for industry. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm291128.pdf\n                    \n                  . Accessed 20 Aug 2018"},{"key":"1907_CR20","unstructured":"FDA. Assay development and validation for immunogenicity testing of therapeutic protein products (draft guidance, 2016). \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM192750.pdf\n                    \n                  . Accessed 31 Jan 2018"},{"key":"1907_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48:1267\u201381.","journal-title":"J Pharm Biomed Anal"},{"key":"1907_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsk\u00fd J, Sylwestrzak A, Leszczy\u0144ski P, Porawska W, Baranauskaite A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:51\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1907_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/jdv.14605","volume":"32","author":"S Gerdes","year":"2018","unstructured":"Gerdes S, Tha\u00e7i D, Griffiths CEM, Arenberger P, Poetzl J, Wuerth G, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018;32:420\u20137.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1907-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1907-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1907-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T23:24:27Z","timestamp":1590535467000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1907-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1907"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1907-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"12 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice and local regulations. An institutional review board or independent ethics committee at each site approved the protocol, consent form, and any other written information provided to patients or their legal representatives. All patients or their legal representatives gave written informed consent prior to study entry.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Janusz Jaworski reports trial payment for this research study and lecture fees from Sandoz. Marco Matucci-Cerinic reports no conflicts of interest. Hendrik Schulze-Koops reports personal fees from Sandoz\/Hexal, during the conduct of the study, and grants and personal fees from Novartis, outside the submitted work. Maya Buch reports personal fees from Sandoz, during the conduct of the study. Eugeniusz J. Kucharz reports no conflict of interest. Yannick Allanore reports personal fees from Sandoz, grants and personal fees from Pfizer, and grants and personal fees from Roche, during the conduct of the study. Arthur Kavanaugh reports personal fees from Sandoz, outside the submitted work. Philip Young and Goran Babic are employees of Hexal AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"130"}}